Gilead Reports Strong Q1, Forecasts Full-Year Net Loss Due to $11.5B IPR&D Charges from Major Acquisitions
GILD sits 37% above its 52-week low of $95.295.
Summary
Gilead Sciences reported strong first-quarter results but revised its full-year outlook to a net loss, driven by an anticipated $11.5 billion in IPR&D charges from recent strategic acquisitions, while also managing extensive legal challenges.
Key Events · Earnings and Guidance · GILD
-
Strong Q1 2026 Financial Performance
Reported total revenues of $7.0 billion, a 4% increase year-over-year, and net income of $2.0 billion, a 54% increase, with diluted EPS of $1.61.
-
Revised Full-Year Outlook to Net Loss
Forecasts a net loss for Q2 and the full year 2026 due to approximately $11.5 billion in acquired in-process R&D (IPR&D) expenses from recent acquisitions.
-
Significant Strategic Acquisitions
Completed the acquisition of Arcellx for $7.1 billion and entered into definitive agreements to acquire Tubulis for up to $5.1 billion and Ouro Medicines for up to $2.2 billion.
-
Debt Management and Financing
Repaid $2.75 billion in senior unsecured notes and secured a new $4.7 billion term loan facility, drawing $1.1 billion in April 2026.
Analysis · GILD · Life Sciences
This quarterly report provides detailed financial results for Q1 2026, showing robust revenue and net income growth. However, the most significant market-moving information is the updated full-year outlook, which forecasts a net loss for Q2 and the entire year 2026. This negative revision is attributed to approximately $11.5 billion in acquired in-process research and development (IPR&D) expenses stemming from recent strategic acquisitions. While these acquisitions (Arcellx, Tubulis, Ouro Medicines) are intended to bolster Gilead's long-term pipeline, the immediate and substantial IPR&D charges will significantly impact near-term profitability. Investors will need to weigh the strategic benefits of these pipeline additions against the considerable short-term earnings dilution. Additionally, the company continues to navigate a complex legal landscape with ongoing product liability and antitrust lawsuits, representing significant potential liabilities, alongside new patent litigation for Descovy.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 40.7% of the 383 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GILD was trading at $130.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.4B. The 52-week trading range was $95.30 to $157.29. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.